India to Sri Lanka: Acarbose Export Trade Route

To import Acarbose formulations into Sri Lanka, the following approvals and registrations are mandatory:

• Marketing Authorization: Importers must obtain a marketing authorization from the NMRA. This involves submitting a comprehensive dossier detailing the product's quality, safety, and efficacy.

• Dossier Format: The NMRA accepts dossiers in the Common Technical Document (CTD) format.

• Approval Timelines: While specific timelines can vary, the NMRA aims to process applications efficiently.

• Product Registration Fees: Fees are applicable for product registration; however, exact amounts should be confirmed directly with the NMRA.

• GMP Inspection Requirements: Foreign manufacturing facilities must comply with Good Manufacturing Practices (GMP) as per NMRA guidelines. The NMRA may conduct GMP inspections of overseas facilities to ensure compliance. (nmra.gov.lk)

Indian manufacturers exporting Acarbose formulations to Sri Lanka must adhere to the following GMP standards:

• GMP Certification: Manufacturers must hold valid GMP certifications recognized by the NMRA. Compliance with WHO-GMP standards is essential.

• Approved Facilities: Manufacturing sites must be approved by the NMRA. This involves submitting a Site Master File and may include on-site GMP inspections. (nmra.gov.lk)

• Recent Inspections and Regulatory Actions: The NMRA conducts routine GMP audits of foreign manufacturing facilities. Any non-compliance identified during these inspections can lead to regulatory actions, including suspension or cancellation of product registrations.

Several regulatory changes have been implemented by the NMRA in recent years:

• Submission of Import Data: Effective January 1, 2025, all import data for pharmaceuticals must be submitted in the specified format to the Market Control Division of the NMRA. (nmra.gov.lk)

• Pharmaceutical Labeling Requirements: As of December 31, 2025, all imported finished pharmaceutical products must carry a price-marked label before release to the local market. The label must display the Maximum Retail Price (MRP) and the name and address of the local marketing authorization holder or importer. (softgroup.eu)

Staying informed about these regulatory requirements and developments is crucial for the successful importation of Acarbose formulations into Sri Lanka.

As of 2024, Sri Lanka's market for acarbose formulations is experiencing growth, driven by an increasing prevalence of type 2 diabetes, which affects approximately 10% of the adult population. The country's healthcare expenditure has been rising, with a focus on enhancing access to antidiabetic medications. While specific data on domestic production of acarbose formulations is limited, the majority of the demand is met through imports, primarily from India.

Pharmaceutical products classified under HS code 30049099, including acarbose formulations, are subject to a 0% import duty in Sri Lanka. Additionally, these imports are exempt from Value Added Tax (VAT) and other local taxes, aligning with the government's policy to ensure affordable access to essential medicines. The India-Sri Lanka Free Trade Agreement (ISFTA) further supports this by allowing duty-free importation of pharmaceutical products from India, enhancing the cost-effectiveness of these imports.

India is the predominant supplier of acarbose formulations to Sri Lanka, accounting for approximately 90% of the total imports in this category. Other countries, including China and various European nations, contribute to the remaining 10% of imports. Indian manufacturers offer competitive pricing, often 15-20% lower than their Chinese and European counterparts, due to lower production costs and the benefits of the ISFTA. This pricing advantage, coupled with established trade relations, positions India as the leading exporter of acarbose formulations to Sri Lanka.

India is a leading global hub for generic pharmaceutical production, accounting for approximately 20% of the global supply by volume. This prominence is underpinned by a robust infrastructure comprising numerous WHO-GMP and FDA-approved facilities dedicated to the manufacture of finished dosage forms, including Acarbose formulations. As of November 2024, India had 134 FDA-registered finished dosage form facilities, reflecting its substantial manufacturing capacity.

The country's cost structure offers significant advantages. Economies of scale, coupled with a well-established supply chain, enable Indian manufacturers to produce Acarbose tablets and capsules at competitive prices without compromising quality. This cost-effectiveness, combined with stringent regulatory compliance, positions India as a preferred source for Acarbose formulations globally.

When comparing Acarbose formulation exports, India offers a compelling balance of cost and quality. Chinese manufacturers, while competitive on price, often face challenges related to regulatory acceptance and quality perception in markets like Sri Lanka. European Union (EU) manufacturers are renowned for high-quality branded generics but typically command higher prices, which may not be cost-effective for all buyers.

Indian Acarbose formulations are produced in facilities adhering to international standards, including WHO-GMP and FDA certifications. This ensures consistent quality and facilitates regulatory acceptance in Sri Lanka. Additionally, India's track record of reliable supply chains and adherence to delivery schedules further enhances its appeal as a sourcing destination.

The India-Sri Lanka Acarbose formulation supply chain is characterized by reliability and substantial manufacturing capacity. Indian manufacturers have invested in state-of-the-art facilities with advanced packaging and cold chain capabilities to ensure product integrity during transit. For instance, Granules India Limited expanded its finished dosage capacity by 40% in 2025, adding an additional 10 billion doses annually.

Regulatory compliance is a cornerstone of Indian pharmaceutical manufacturing. Facilities undergo regular inspections by international agencies, including the FDA and WHO, ensuring adherence to global quality standards. This commitment minimizes the risk of supply disruptions due to regulatory non-compliance.

While no significant supply disruptions have been reported recently, buyers are advised to maintain open communication with suppliers to stay informed about any potential issues.

For Sri Lankan buyers sourcing Acarbose from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of Acarbose formulations.

• Minimum Order Quantities (MOQs): Negotiate MOQs that align with your demand forecasts. Indian manufacturers typically offer flexible MOQs, but establishing clear agreements is essential to avoid overstocking or stockouts.

• Payment Terms: Standard payment terms in the India-Sri Lanka pharmaceutical trade often include letters of credit (LC) or advance payments. Clarify and negotiate terms that align with your financial planning and cash flow requirements.

• Supplier Qualification Process: Conduct thorough due diligence on potential suppliers. This includes verifying regulatory certifications (e.g., WHO-GMP, FDA approvals), assessing manufacturing capabilities, and reviewing compliance histories to ensure product quality and supply reliability.

• Regulatory Compliance: Ensure that the selected suppliers' products meet Sri Lanka's regulatory requirements. Collaborate with local regulatory authorities to facilitate smooth importation and distribution processes.

By implementing these strategies, Sri Lankan buyers can establish a robust and reliable supply chain for Acarbose formulations sourced from India.